Volume 61, Issue 5, Pages (November 2014)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
Valérie Vilgrain, Bernard E. Van Beers, Catherine M. Pastor 
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
The management of childhood liver diseases in adulthood
Volume 49, Issue 5, Pages (November 2008)
Volume 53, Issue 5, Pages (November 2010)
Volume 116, Issue 2, Pages (February 1999)
Immigration and viral hepatitis
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Hepatitis B and C virus-related carcinogenesis
Regulatory T-cell directed therapies in liver diseases
The evidence supports a viral aetiology for primary biliary cirrhosis
Living donor liver transplantation: is the hype over?
The place of downstaging for hepatocellular carcinoma
Vps33b is crucial for structural and functional hepatocyte polarity
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Volume 68, Issue 1, Pages (January 2018)
Regulatory T-cell directed therapies in liver diseases
Hepatitis C core protein – The “core” of immune deception?
Jean-Charles Nault, Peter R. Galle, Jens U. Marquardt 
Hypoxia inducible factors in liver disease and hepatocellular carcinoma: Current understanding and future directions  Garrick K. Wilson, Daniel A. Tennant,
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Volume 57, Issue 2, Pages (August 2012)
Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts  Chiara Raggi, Pietro Invernizzi,
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Why men are at higher risk for hepatocellular carcinoma?
Volume 44, Issue 1, Pages (January 2006)
Volume 41, Issue 5, Pages (November 2004)
Genomic risk of hepatitis C-related hepatocellular carcinoma
Autophagy in the liver Journal of Hepatology
Volume 53, Issue 5, Pages (November 2010)
EASL Clinical Practice Guidelines: Wilson’s disease
Volume 62, Issue 2, Pages (February 2015)
Volume 54, Issue 5, Pages (May 2011)
Hepatitis B and C virus-related carcinogenesis
Volume 57, Issue 5, Pages (November 2012)
Volume 50, Issue 4, Pages (April 2009)
Non-invasive diagnosis and biomarkers in alcohol-related liver disease
Volume 52, Issue 5, Pages (May 2010)
Paul C. Adams, James C. Barton  Journal of Hepatology 
Volume 56, Issue 6, Pages (June 2012)
Chetana Lim, Chady Salloum, Daniel Azoulay
Immigration and viral hepatitis
Evolution of liver transplantation for hepatocellular carcinoma
Kornelius Schulze, Jean-Charles Nault, Augusto Villanueva 
Role of desmoplasia in cholangiocarcinoma and hepatocellular carcinoma
Volume 63, Issue 1, Pages (July 2015)
Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences  Zobair M. Younossi, Aybike Birerdinc,
Volume 66, Issue 3, Pages (March 2017)
Volume 62, Issue 3, Pages (March 2015)
Vincenzo Mazzaferro, Andrea Pulvirenti, Jorgelina Coppa 
Volume 65, Issue 4, Pages (October 2016)
New trials and results in systemic treatment of HCC
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Genetic alterations in advanced HBV-related HCC with portal vein tumor thrombosis: Insights from next generation DNA sequencing  Roongruedee Chaiteerakij,
Chimeric mouse model of hepatitis B virus infection
Volume 44, Issue 1, Pages (January 2006)
Volume 58, Issue 2, Pages (February 2013)
The relationship between age and fat infiltration in liver and muscle
Genetics of hepatocellular carcinoma: The next generation
Volume 53, Issue 1, Pages (July 2010)
Volume 67, Issue 5, Pages (November 2017)
Presentation transcript:

Volume 61, Issue 5, Pages 1178-1183 (November 2014) Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations  Sílvia Vilarinho, E. Zeynep Erson-Omay, Akdes Serin Harmanci, Raffaella Morotti, Geneive Carrion-Grant, Jacob Baranoski, A.S. Knisely, Udeme Ekong, Sukru Emre, Katsuhito Yasuno, Kaya Bilguvar, Murat Günel  Journal of Hepatology  Volume 61, Issue 5, Pages 1178-1183 (November 2014) DOI: 10.1016/j.jhep.2014.07.003 Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Proband’s germline genetic analysis and liver background histology. Compound heterozygous missense mutations in ABCB11: R1226H and A389P, and their conservation across species (A and B respectively). (C) Trichrome stain of the background liver (10×). (D) Abnormal cytokeratin-7 expression by hepatocytes in peri-central vein location (10×). (E) Normal canalicular BSEP expression in the background hepatic parenchyma (20×). Journal of Hepatology 2014 61, 1178-1183DOI: (10.1016/j.jhep.2014.07.003) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Proband’s HCC somatic driver mutations, copy number profile, clonal evolution and histology. (A) CTNNB1 somatic mutation, S33P. (B) NFE2L2 somatic mutation, D27_L30delID. (C) The log ratio of Depth of Coverage of each exon between tumour and blood is shown as gray dots. The black lines represent the segmental copy neutral events. (D) The difference between minor allele frequency in blood and in the tumour shows no regions of loss of heterozygosity. (E) Mutations having a clonality rate ⩾0.8 are identified to be clonal whereas mutations with a clonality rate <0.8 are identified to be subclonal. CTNNB1 has a clonality rate of 0.95 and NFE2L2 has a clonality rate of 0.60. (F) Temporal relationship of CTNNB1 and NFE2L2 mutations. (G) H&E stain shows interface between well-differentiated and poorly differentiated components of HCC (10×). (H) Beta catenin immunostain in poorly differentiated and better differentiated areas of the HCC. The poorly differentiated portion shows strong immunostaining in both nucleus and cytoplasm. The better differentiated portion (bottom left) shows only strong nuclear positivity (20×). Journal of Hepatology 2014 61, 1178-1183DOI: (10.1016/j.jhep.2014.07.003) Copyright © 2014 European Association for the Study of the Liver Terms and Conditions